ISSN: 2161-0681

Jornal de Patologia Clínica e Experimental

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Indexado em
  • Índice Copérnico
  • Google Scholar
  • Sherpa Romeu
  • Abra o portão J
  • Genâmica JournalSeek
  • JornalTOCs
  • Diretório de Periódicos de Ulrich
  • RefSeek
  • Universidade Hamdard
  • EBSCO AZ
  • OCLC – WorldCat
  • Publons
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • ICMJE
Compartilhe esta página

Abstrato

Nomogram Based Survival Predictions of Patients with Soft Tissue Cancer Including Heart in the United States

Roungu Ahmmad

Introduction: This study aimed to assess the effects of cancer treatment on sarcoma types and to predict overall survival probabilities using nomograms.

Methods: This study uses the SEER-18 database, version 2020, sponsored by the National Cancer Institute (NCI). The study cohort included participants diagnosed between 2000 and 2018 with soft tissue cancers including heart. A multivariable stratified Cox proportional hazards model was applied to predict mortality rate and nomograms were used to predict overall survival probability.

Results: The median survival time for 24,849 study participants was 48 months (IQR: 19-102) with Spindle cell Sarcoma (ScS) having a shorter median survival time compared with Liposarcoma (LiS). A significant number of Soft Tissue Sarcoma (STS) patients had surgery, where surgery on ScS improved survival by 75% (HR: 0.25, 95% CI: 0.19-0.32, p<0.001) and those who received radiation had a 26% improvement (HR: 0.74, 95% CI: 0.61-0.89, p=0.001). Furthermore, chemotherapy on GcS resulted in a 40% reduction in mortality for patients compared to those who did not receive chemotherapy (HR: 0.60, 95% CI: 0.45-0.80, p<0.001). Based on nomogram, after two, five and ten years, a patient who received surgery on their primary sites would have a survival rate of approximately 90%. In contrast, a patient who did not receive surgery on their primary sites would only live for 20% or less. Patients with MyS have a 90% chance of surviving for 5 and 10 years after surgical intervention, but only 22% and 10% without surgery.

Conclusion: Based on the results of this study, surgical and radiation intervention was associated with improved survival in patients with STS, while chemotherapy and primary systemic therapy had contradictory effects.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.